title: Metabotropic Glutamate 2/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A Review.
abstract: Schizophrenia and Bipolar Disorder are chronic psychiatric disorders, both considered as "major psychosis"; they are thought to share some pathogenetic factors involving a dysfunctional gene x environment interaction. Alterations in the glutamatergic transmission have been suggested to be involved in the pathogenesis of psychosis. Our group developed an epigenetic model of schizophrenia originated by Prenatal Restraint Stress (PRS) paradigm in mice. PRS mice developed some behavioral alterations observed in schizophrenic patients and classic animal models of schizophrenia, i.e. deficits in social interaction, locomotor activity and prepulse inhibition. They also showed specific changes in promoter DNA methylation activity of genes related to schizophrenia such as reelin, BDNF and GAD67, and altered expression and function of mGlu2/3 receptors in the frontal cortex. Interestingly, behavioral and molecular alterations were reversed by treatment with mGlu2/3 agonists. Based on these findings, we speculate that pharmacological modulation of these receptors could have a great impact on early phase treatment of psychosis together with the possibility to modulate specific epigenetic key protein involved in the development of psychosis. In this review, we will discuss in more details the specific features of the PRS mice as a suitable epigenetic model for major psychosis. We will then focus on key proteins of chromatin remodeling machinery as potential target for new pharmacological treatment through the activation of metabotropic glutamate receptors.
authors.affiliation: Psychiatry and Behavioral Science, Northwestern University, Feinberg School of Medicine, 303E Chicago Ave, Chicago, IL 60611. fmatrisciano@hotmail.com.
authors.forename: Francesco
authors.initials: F
authors.lastname: Matrisciano
authors.forename: Isabella
authors.initials: I
authors.lastname: Panaccione
authors.forename: Danis R
authors.initials: DR
authors.lastname: Grayson
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Nicoletti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Guidotti
mesh_terms: D000818:Animals; D019175:DNA Methylation / Q000502:physiology; D044127:Epigenesis, Genetic / Q000502:physiology*; D005625:Frontal Lobe / Q000378:metabolism / Q000473:pathology; D006801:Humans; D011618:Psychotic Disorders / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics / Q000378:metabolism*; D000091042:Reelin Protein
chemical_list: D018094:Receptors, Metabotropic Glutamate; D000091042:Reelin Protein; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3; C000717127:RELN protein, human; C000717128:Reln protein, mouse
references.citation: Schizophr Bull. 2008 Sep;34(5):944-61
references.pmid: 18586694
references.citation: Mol Psychiatry. 2014 Jun;19(6):641-51
references.pmid: 24751963
references.citation: Psychoneuroendocrinology. 2013 Apr;38(4):509-21
references.pmid: 22910687
references.citation: Mol Pharmacol. 2013 Jun;83(6):1166-75
references.pmid: 23508685
references.citation: J Pharmacol Exp Ther. 2000 Jan;292(1):76-87
references.pmid: 10604933
references.citation: Mol Pharmacol. 2007 Aug;72(2):477-84
references.pmid: 17526600
references.citation: Science. 1998 Aug 28;281(5381):1349-52
references.pmid: 9721099
references.citation: Trends Biochem Sci. 2003 Sep;28(9):461-3
references.pmid: 13678953
references.citation: Mol Pharmacol. 2011 Jul;80(1):174-82
references.pmid: 21505039
references.citation: Transl Psychiatry. 2012;2:e159
references.pmid: 22948384
references.citation: Dev Psychopathol. 1999 Summer;11(3):525-43
references.pmid: 10532623
references.citation: Psychopharmacology (Berl). 2011 Mar;214(1):89-106
references.pmid: 20949351
references.citation: J Neurosci. 2011 Feb 2;31(5):1863-72
references.pmid: 21289196
references.citation: Schizophr Res. 2012 Apr;136(1-3):160-1
references.pmid: 22300789
references.citation: Nature. 2008 Mar 6;452(7183):93-7
references.pmid: 18297054
references.citation: Psychopharmacology (Berl). 2005 Jul;180(2):191-205
references.pmid: 15864560
references.citation: Mol Pharmacol. 2002 May;61(5):989-96
references.pmid: 11961116
references.citation: Psychopharmacology (Berl). 2000 Mar;148(4):423-9
references.pmid: 10928316
references.citation: Essays Biochem. 2010 Sep 20;48(1):275-87
references.pmid: 20822499
references.citation: Psychopharmacology (Berl). 2004 Mar;172(2):233-40
references.pmid: 14598016
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9341-6
references.pmid: 15961543
references.citation: Bioessays. 1998 Aug;20(8):615-26
references.pmid: 9780836
references.citation: Neuropsychopharmacology. 2012 Mar;37(4):929-38
references.pmid: 22089319
references.citation: Biol Psychiatry. 2004 May 15;55(10):965-70
references.pmid: 15121478
references.citation: Neuropsychopharmacology. 2013 Jan;38(1):183-97
references.pmid: 22643929
references.citation: Trends Pharmacol Sci. 2010 Apr;31(4):153-60
references.pmid: 20064669
references.citation: Trends Cell Biol. 2014 Nov;24(11):664-74
references.pmid: 25242115
references.citation: Nat Med. 2007 Sep;13(9):1102-7
references.pmid: 17767166
references.citation: EMBO J. 1998 Sep 1;17(17):4905-8
references.pmid: 9724627
references.citation: Arch Gen Psychiatry. 1987 Jul;44(7):660-9
references.pmid: 3606332
references.citation: Am J Hum Genet. 2008 Mar;82(3):696-711
references.pmid: 18319075
references.citation: Cell. 2011 Nov 23;147(5):1011-23
references.pmid: 22118459
references.citation: Science. 2013 Mar 1;339(6123):1095-9
references.pmid: 23449593
references.citation: Schizophr Res. 2015 Sep;167(1-3):35-41
references.pmid: 25476119
references.citation: Cold Spring Harb Symp Quant Biol. 2004;69:67-70
references.pmid: 16117634
references.citation: Schizophr Res. 2007 Mar;91(1-3):51-61
references.pmid: 17270400
references.citation: Curr Psychiatr. 2013 Mar 1;12(3):24-33
references.pmid: 24443645
references.citation: Neuropharmacology. 2011 Jun;60(7-8):1017-41
references.pmid: 21036182
references.citation: Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4804-9
references.pmid: 23382250
references.citation: Neuropharmacology. 2013 May;68:184-94
references.pmid: 22564440
references.citation: J Biol Chem. 2001 Sep 28;276(39):36734-41
references.pmid: 11473107
references.citation: Psychopharmacology (Berl). 2011 Oct;217(3):443-52
references.pmid: 21487651
references.citation: J Neurogenet. 2014 Mar-Jun;28(1-2):41-52
references.pmid: 24702539
references.citation: Brain Res Brain Res Rev. 2000 Mar;31(2-3):302-12
references.pmid: 10719157
references.citation: Neuropsychopharmacology. 2013 Jan;38(1):138-66
references.pmid: 22948975
references.citation: Neuropharmacology. 2004 Dec;47(8):1135-45
references.pmid: 15567423
references.citation: Neuropharmacology. 2011 Jun;60(7-8):1007-16
references.pmid: 21074545
references.citation: J Biol Chem. 2012 Dec 28;287(53):44301-19
references.pmid: 23129762
references.citation: Biol Psychiatry. 2014 Feb 15;75(4):307-15
references.pmid: 23938317
references.citation: Eur J Pharmacol. 2000 Jul 21;400(2-3):221-4
references.pmid: 10988337
references.citation: Schizophr Bull. 2009 May;35(3):528-48
references.pmid: 19223657
references.citation: J Neurosci. 2013 Jan 16;33(3):1088-98
references.pmid: 23325246
references.citation: Neurobiol Dis. 2012 May;46(2):255-62
references.pmid: 22182689
references.citation: Arch Gen Psychiatry. 2008 Feb;65(2):146-52
references.pmid: 18250252
references.citation: Schizophr Res. 2013 Dec;151(1-3):12-9
references.pmid: 24257517
references.citation: JAMA Psychiatry. 2014 Apr;71(4):454-6
references.pmid: 24499927
references.citation: Transl Psychiatry. 2014;4:e418
references.pmid: 25072323
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):215-25
references.pmid: 12769628
references.citation: J Clin Psychopharmacol. 2011 Jun;31(3):349-55
references.pmid: 21508856
references.citation: Trends Neurosci. 2008 May;31(5):234-42
references.pmid: 18395805
references.citation: Mol Interv. 2003 Jun;3(4):220-9
references.pmid: 14993449
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13614-9
references.pmid: 18757738
references.citation: Environ Health Prev Med. 2008 Jan;13(1):16-24
references.pmid: 19568875
references.citation: Trends Pharmacol Sci. 2009 Feb;30(2):55-60
references.pmid: 19110320
references.citation: Schizophr Res. 2013 Nov;150(2-3):434-41
references.pmid: 24035403
references.citation: Nat Neurosci. 2012 Sep;15(9):1245-54
references.pmid: 22864611
references.citation: Biol Psychiatry. 2015 Mar 15;77(6):589-96
references.pmid: 25444166